Boston Scientific Corp.

Find Ratings Reports
BSX : NYSE : Health Technology
$27.2 up 0.11 | 0.41%
Today's Range: 27.061 - 27.475
Avg. Daily Volume: 9655500.0
02/16/18 - 4:01 PM ET

Financial Analysis


BOSTON SCIENTIFIC CORP's gross profit margin for the fourth quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY17 Q4 FY16
Net Sales ($mil)2408.02191.0
EBITDA ($mil)0.0595.0
EBIT ($mil)475.0382.0
Net Income ($mil)-615.0124.0


Balance Sheet Q4 FY17 Q4 FY16
Cash & Equiv. ($mil)0.0439.0
Total Assets ($mil)0.018096.0
Total Debt ($mil)0.05484.0
Equity ($mil)0.06733.0


Profitability Q4 FY17 Q4 FY16
Gross Profit Margin65.9975.17
EBITDA Margin0.027.15
Operating Margin19.7317.43
Sales Turnover0.00.46
Return on Assets0.01.91
Return on Equity0.05.15
Debt Q4 FY17 Q4 FY16
Current Ratio0.00.9
Debt/Capital0.00.45
Interest Expense57.058.0
Interest Coverage8.336.59


Share Data Q4 FY17 Q4 FY16
Shares outstanding (mil)1372.741362.11
Div / share0.00.0
EPS-0.450.09
Book value / share0.04.94
Institutional Own % n/a n/a
Avg Daily Volume9966905.05257824.0

Valuation


BUY. BOSTON SCIENTIFIC CORP's P/E ratio indicates a significant premium compared to an average of 106.37 for the Health Care Equipment & Supplies industry and a significant premium compared to the S&P 500 average of 25.51. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BSX 387.00 Peers 106.37   BSX NA Peers 51.45

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

BSX is trading at a significant premium to its peers.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BSX 17.53 Peers 26.79   BSX 0.86 Peers 0.85

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

BSX is trading at a significant discount to its peers.

 

Average. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

BSX trades at a valuation on par to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BSX NA Peers 5.71   BSX -73.08 Peers -2.55

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

Ratio not available.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, BSX is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BSX 4.11 Peers 5.74   BSX 7.89 Peers 16.53

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BSX is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BSX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades